TKPHF (Takeda Pharmaceutical Co) Short-Term Debt: $3,234 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TKPHF Takeda Pharmaceutical Co Ltd TKPHF
77 GF Score
Price $35.89
GF Value $29.62
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Short-Term Debt?

Takeda Pharmaceutical Co TKPHF +2.72% 77 Short-Term Debt is $3,234 Mil as of Jun. 2026. GuruFocus rates TKPHF with a GF Score™ of 77/100 and a GF Value™ of $29.62 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Takeda Pharmaceutical Co's Short-Term Debt for the quarter that ended in Jun. 2026 was $3,234 Mil.

Takeda Pharmaceutical Co's quarterly Short-Term Debt declined from Dec. 2025 ($3,740 Mil) to Mar. 2026 ($3,228 Mil) but then increased from Mar. 2026 ($3,228 Mil) to Jun. 2026 ($3,234 Mil).

Takeda Pharmaceutical Co's annual Short-Term Debt increased from Mar. 2024 ($2,451 Mil) to Mar. 2025 ($3,683 Mil) but then declined from Mar. 2025 ($3,683 Mil) to Mar. 2026 ($3,228 Mil).

Takeda Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Takeda Pharmaceutical Co Short-Term Debt Related Terms

Takeda Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Short-Term Debt Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,720.34 2,540.69 2,451.30 3,682.73 3,227.55

Takeda Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,568.76 1,987.37 3,740.16 3,227.55 3,234.25
TKPHF
77GF Score
Takeda Pharmaceutical Co Ltd TKPHF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $3,234 Mil mean?
Takeda Pharmaceutical Co (TKPHF) has a Short-Term Debt of $3,234 Mil as of Jun. 2026.
Is Takeda Pharmaceutical Co's Short-Term Debt too high?
Takeda Pharmaceutical Co's current Short-Term Debt is $3,234 Mil. Overall, Takeda Pharmaceutical Co has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Short-Term Debt compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Short-Term Debt of $3,234 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Takeda Pharmaceutical Co's current Short-Term Debt is $3,234 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TKPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $29.62, compared to a current price of $35.89 — trading 21.2% above its estimated fair value. The current Short-Term Debt is $3,234 Mil. Takeda Pharmaceutical Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TKPHF), the current Short-Term Debt is $3,234 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (TKPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of $35.89 is trading 21.2% above its estimated GF Value™ of $29.62. GuruFocus considers Takeda Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for TKPHF:

  • Short-Term Debt: $3,234 Mil
  • GF Value™: $29.62 vs. price of $35.89 (21.2% above fair value)
  • GF Score™: 77/100 with 10 warning signs

No single metric tells the full story. See the TKPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
77GF Score

Get the complete analysis for TKPHF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.89
Price
$29.62
GF Value